Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cel-Sci Corp (NY: CVM ) 1.130 +0.010 (+0.89%) Official Closing Price Updated: 6:30 PM EDT, Aug 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Cel-Sci Corp < Previous 1 2 3 4 5 6 Next > CVM Stock Earnings: CEL-SCI Misses EPS for Q3 2024 August 16, 2024 CVM stock results show that CEL-SCI missed analyst estimates for earnings per share the third quarter of 2024. Via InvestorPlace CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results August 15, 2024 From CEL-SCI Corporation Via Business Wire BioMedNewsBreaks — CEL-SCI Corp. (NYSE American: CVM) Closes on $10.8M Best-Efforts Offering August 02, 2024 Via Investor Brand Network Exposures Product Safety CEL-SCI Announces Closing of $10.8 Million Offering July 29, 2024 From CEL-SCI Corporation Via Business Wire CVM Stock Earnings: CEL-SCI Reported Results for Q2 2024 May 16, 2024 CEL-SCI just reported results for the second quarter of 2024. Via InvestorPlace Why CEL-SCI Corporation (CVM) Shares Are Diving February 09, 2024 CEL-SCI Corporation shares are trading lower by 13.9% Friday morning. The company priced an offering of 3.875 million shares. Via Benzinga CVM Stock Earnings: CEL-SCI Reported Results for Q4 2023 December 27, 2023 CEL-SCI just reported results for the fourth quarter of 2023. Via InvestorPlace Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session July 26, 2024 Via Benzinga CEL-SCI Announces Pricing of $10.8 Million Offering July 26, 2024 From CEL-SCI Corporation Via Business Wire CEL-SCI’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results July 26, 2024 From CEL-SCI Corporation Via Business Wire CEL-SCI Appoints Robert Watson as Chairperson of the Board July 08, 2024 From CEL-SCI Corporation Via Business Wire CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population June 18, 2024 From CEL-SCI Corporation Via Business Wire Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor June 06, 2024 From CEL-SCI Corporation Via Business Wire CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results May 16, 2024 From CEL-SCI Corporation Via Business Wire 12 Health Care Stocks Moving In Thursday's Pre-Market Session May 09, 2024 Via Benzinga Why CEL-SCI (CVM) Shares Are Trading Higher May 08, 2024 CEL-SCI shares are trading higher by 18.6% during Wednesday's session. The company received positive feedback from the FDA regarding their cancer immunotherapy. Via Benzinga Exposures Product Safety CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer May 08, 2024 From CEL-SCI Corporation Via Business Wire 12 Health Care Stocks Moving In Wednesday's Pre-Market Session May 08, 2024 Via Benzinga CEL-SCI Appoints Mario Gobbo to Its Board of Directors April 23, 2024 From CEL-SCI Corporation Via Business Wire CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology March 19, 2024 From CEL-SCI Corporation Via Business Wire CEL-SCI Corporation Issues Letter to Shareholders March 06, 2024 From CEL-SCI Corporation Via Business Wire CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results February 15, 2024 From CEL-SCI Corporation Via Business Wire InvestorNewsBreaks – CEL-SCI Corporation (NYSE American: CVM) Closes on $7.75M Public Offering February 14, 2024 Via Investor Brand Network Exposures Product Safety CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock February 13, 2024 From CEL-SCI Corporation Via Business Wire 12 Health Care Stocks Moving In Friday's Intraday Session February 09, 2024 Via Benzinga CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock February 09, 2024 From CEL-SCI Corporation Via Business Wire CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug February 06, 2024 From CEL-SCI Corporation Via Business Wire European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine® January 31, 2024 From CEL-SCI Corporation Via Business Wire 12 Health Care Stocks Moving In Thursday's After-Market Session December 28, 2023 Via Benzinga CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments December 22, 2023 From CEL-SCI Corporation Via Business Wire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.